Xenon Pharmaceuticals Inc (XENE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Xenon Pharmaceuticals Inc (XENE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH132674D
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc is a drug development company that discovers and develops of therapeutics for orphan indications. The company's pipeline products comprise Glybera, XEN801, sodium channel inhibitor and TV-45070. It discovers various validated drug targets through the study of rare human diseases with extreme traits, including channelopathies, diseases caused by mutations in ion channels. The company's target treatment areas comprise lipoprotein lipase deficiency, cardiovascular diseases, dermatology, pain and dravet syndrome. It operates through partnerships with other drug developers. Xenon is headquartered in Burnaby, British Columbia, Canada.

Xenon Pharmaceuticals Inc (XENE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Xenon Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 12

Partnerships 13

Medpace Enters into Amendment Agreement with Xenon Pharma 13

Xenon Pharma Extends Agreement with Genentech 13

Licensing Agreements 14

Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 14

Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 15

Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 16

Xenon Pharma Extends Licensing Agreement with Genentech 18

Equity Offering 19

Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 19

Xenon Pharma Raises USD41.4 Million in IPO of Shares 20

Xenon Pharmaceuticals Inc-Key Competitors 23

Key Employees 24

Locations And Subsidiaries 25

Head Office 25

Recent Developments 26

Financial Announcements 26

May 09, 2017: Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 26

Mar 08, 2017: Xenon Pharmaceuticals Reports 2016 Financial Results and Provides Corporate Update 28

Nov 03, 2016: Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update 30

Aug 03, 2016: Xenon Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update 32

May 10, 2016: Xenon Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update 34

Mar 08, 2016: Xenon Pharmaceuticals Reports 2015 Financial Results and Provides Corporate Update 36

Corporate Communications 38

Sep 27, 2016: Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors 38

Product News 39

06/08/2016: Xenon Pharmaceuticals Presents Update on Nav1.6 Sodium Channel Inhibitor at the Jefferies 2016 Healthcare Conference 39

Clinical Trials 40

Jun 08, 2016: Xenon Pharmaceuticals Presents Corporate Update and Highlights Its Proprietary Therapeutic XEN801 Program at the Jefferies 2016 Healthcare Conference 40

Feb 10, 2016: Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne 41

Other Significant Developments 42

Jan 08, 2017: Xenon Pharmaceuticals Outlines Key Milestones for 2017 42

Mar 31, 2016: Xenon Pharmaceuticals to Provide Business and Milestone Update at Needham Healthcare Conference 43

Jan 11, 2016: Xenon Outlines Key Milestones for 2016 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45

List of Figures

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Xenon Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Xenon Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Xenon Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10

Xenon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Xenon Pharmaceuticals Acquires Development and Commercialization Rights for XEN1101 from 1st Order 12

Medpace Enters into Amendment Agreement with Xenon Pharma 13

Xenon Pharma Extends Agreement with Genentech 13

Xenon Pharma Exercises Option For Licensing Agreement With Isis Pharma For Antisense Drug XEN701 14

Merck Exercises Option For Licensing Agreement With Xenon Pharma For Cardiovascular Disease Targeted Compounds 15

Xenon Pharma Enters Into Licensing Agreement With Teva Pharma For XEN402 16

Xenon Pharma Extends Licensing Agreement with Genentech 18

Xenon Pharma Completes Public Offering of Shares for USD34.5 Million 19

Xenon Pharma Raises USD41.4 Million in IPO of Shares 20

Xenon Pharmaceuticals Inc, Key Competitors 23

Xenon Pharmaceuticals Inc, Key Employees 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Xenon Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16065
Site License
USD 500 INR 32130
Corporate User License
USD 750 INR 48195

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com